Optimi Health’s Psilocybin Capsules Join Medibank’s Expanded Mental Health Program

An announcement from Optimi Health ( (TSE:OPTI) ) is now available.

Optimi Health’s 5mg psilocybin capsules have been selected for inclusion in Medibank’s psychotherapy program, which has expanded to cover Treatment-Resistant Depression. This inclusion marks a significant step for Optimi as it integrates its products into insurance-backed regulated care, highlighting the growing acceptance of psychedelic medicines in mental health treatment. Medibank’s initiative is part of a broader AUD $50 million commitment to enhance mental health access and innovation, reinforcing the strategic shift towards novel therapies like psilocybin and MDMA.

Spark’s Take on TSE:OPTI Stock

According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.

Optimi Health’s overall stock score is primarily influenced by its financial performance, which shows potential but is overshadowed by significant risks due to persistent losses and negative cash flows. Technical analysis provides a moderate positive outlook with short-term bullish signals, while valuation remains a concern due to ongoing losses and lack of dividends.

To see Spark’s full report on TSE:OPTI stock, click here.

More about Optimi Health

Optimi Health Corp. is a Canadian pharmaceutical drug manufacturer compliant with Good Manufacturing Practices (GMP) and licensed by Health Canada for handling controlled substances. The company operates two 10,000-square-foot facilities in British Columbia, supplying active pharmaceutical ingredients and finished dosage forms to regulated channels. Optimi’s products are available for prescription use in Australia through the Authorized Prescriber Scheme and accessible in Canada via the Special Access Program.

Average Trading Volume: 106,896

Technical Sentiment Signal: Buy

Current Market Cap: C$38.17M

See more insights into OPTI stock on TipRanks’ Stock Analysis page.